The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
Might be worth a search of say AIM listed Pharma companies with a market cap of less than £4m that meet the criteria specified in the RNS.
More likely initial rise around 8am was FOMO followed by current drop being profit taking from yesterday and over the last week. This should settle soon IMO. Nothing to panic about- the recent news speaks for itself, as ever, patience needed but heading in the right direction
Angle won’t want a placing at this price, like C4X, Redx and Oxford Cannaboid they may decide to delist - for Pharma companies there should be a better prospect of raising capital at a better price once delisted from the Wild West that is AIM
I can’t see Angle wanting to do a placing based on current SP even though a raise may not be needed until say mid 2025. If things don’t change re LSE/AIM by then, then don’t be surprised if this goes private like C4X, Redx etc for the same reasons those companies went private. Still, who knows what might happen in next 12 months, with more deals / tie ups we could become cash flow positive and obviate any need for a capital raise
You hold them for the long term and hope that the true valuation will be recognised away from AIM. Yet another Pharma company to delist from AIM.
The cash balance at 31.12.23 was £6.1m and they were due to run out in Aug 24. About to raise £6.3m - yikes, how long will that last? The cash burn is phenomenal. Need to land more meaningful revenue generating contracts soon otherwise we’re back to square one in no time.
Would be good to hear from AN again with an update. While this is a good RNS by itself, the momentum should build as a result of a series of positive updates so far in 2024. Point is, this isn’t a one off. Hopefully the timing of the next placing (if there is to be one, though presumably not until at least Q1 2025) has been kicked forward by a few months. IMO this is significantly undervalued and ought to be a fantastic recovery stock when the AIM market recovers.
Had a feeling this was coming as the share price recently increased out of nowhere for no apparent reason. Glad I sold for 2.25p earlier this week. Will get back in when SP drops as the company will be funded and hopefully all the collaborations and partnerships news will bear economic fruition (ie: will be meaningfully revenue generative). If I still held shares I would be outraged at the level of discount re the placing price, but this is the current tragedy of AIM, and although I’ve escaped on this share, I have been caught holding the baby on other heavily discounted placings on other shares (ENET and CPX being 2 recent ones). AIM market doesn’t do itself any favours these days.
It’s not a pump, it’s a recovery. There is a difference.
TwoGoodToDie, lol, I want to buy some cheap shares too and also missed out before yesterday’s news. I initially thought £150,000 over 6 months was feeble but the Proactive interview with Andrew Newland provided context and reminded us of 3 other RNSs of great news in 2024 so far. While a SP target of 70p is probably presently unrealistic due to the state of the AIM market it seems this share’s SP has been at or around the bottom of its range, until yesterday that is. I expect it to rise into the 20’s especially when the US patent position is confirmed alongside the EU patent.
Investor.Meet Company (not Investment)
The Investment Meet Company webinar was a joke. An absolute joke. You would have thought they could have used this as an opportunity to address recent issues around placements, suspension etc and provide some reassurance for shareholders. Not impressed .
Begs the question why haven’t the cornerstone investors sold? There may be the prospect of a sale / takeover and the Chinese in pole position as one BRICS country buys a key resource in another BRICS country or the yanks get in first to get ahead of the Chinese. If this was all over the plug would have been pulled. IMO and DYOR
Can’t buy ATM
Agreed it does look oversold IMO and it is worth a punt at this level. Just don’t invest more than you can afford to lose
As the company has 2 projects, what is happening to the Vermelho project, and what is the likelihood the Chinese will come in and buy this given low MCap of the company. There might still be some life in this share.
If they do need to do (yet) another placing let’s hope it’s after new contracts are announced so that the placing will be at a much higher SP
At least the company is communicating with shareholders and the RNS is really good even if we already knew most of it. Hopefully this is not a softener that turns out to be a prelude to a placing. If there is to be a placing (and let’s face it, that is the only way the company can raise funds at present) then please don’t let it be a heavily discounted placing as there’s no need for it now that we’ve hit helium and hydrogen since the woeful December placing. A placing does not have to be a bad thing in the circumstances
Not sure why this will catch the shorters out as results are more or less as expected with no real surprises (good or bad). I predict SP to rise to early 70p. The real reaction may come when Q1 results are published but even then expectations have already been set. This is a long term investment and is looking good but it isn’t a get rich quick scenario unless the market suddenly accepts how significantly this company is undervalued and has been for some time.
Why does an adjournment to the meeting tank the SP? It wasn’t as if the topics of the meeting would have been value enhancing